Title

The feasibility and safety of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy: initial first in man clinical results.

Document Type

Article

Publication Date

11-15-2015

Publication Title

International journal of cardiology

Abstract

BACKGROUND: A tissue engineering approach to augment the left ventricular wall has been suggested as a means to treat patients with advanced heart failure. This study evaluated the safety and feasibility of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy undergoing open-heart surgery.

METHODS AND RESULTS: Eleven male patients (aged 44 to 74years) with advanced heart failure (NYHA class 3 or 4), a left ventricular ejection fraction (LVEF) of

CONCLUSIONS: Administration of Algisyl-LVR to patients with advanced HF at the time of cardiac surgery is feasible and safe; warranting continued development of Algisyl-LVR as a potential therapy in patients with advanced HF.

Medical Subject Headings

Adolescent; Adult; Aged; Alginates; Cardiac Surgical Procedures; Cardiomyopathy, Dilated; Echocardiography; Electrocardiography, Ambulatory; Feasibility Studies; Female; Follow-Up Studies; Heart Ventricles; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Injections; Male; Middle Aged; Stroke Volume; Time Factors; Tissue Engineering; Treatment Outcome; Ventricular Function, Left; Young Adult

PubMed ID

26173169

Volume

199

First Page

18

Last Page

24

Share

COinS